BlackRock Amends Amicus Therapeutics Stake (Amendment No. 8)
Ticker: FOLD · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Amicus Therapeutics stake, signaling a passive investment change.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating a change in its ownership of Amicus Therapeutics Inc. common stock as of December 31, 2023. This filing, Amendment No. 8, shows BlackRock's updated passive investment stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or strategy regarding Amicus Therapeutics, potentially influencing other investors' perceptions of the stock.
Why It Matters
Large institutional investors like BlackRock often conduct extensive due diligence; their buying or selling activity can be seen as a vote of confidence or concern for a company's future prospects.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate, significant risk to the company or its stock.
Analyst Insight
Investors should note BlackRock's continued passive interest in Amicus Therapeutics, but this filing alone doesn't provide enough detail to warrant immediate action. Further investigation into BlackRock's specific percentage ownership and any changes from previous filings would be prudent.
Key Numbers
- 03152W109 — CUSIP Number (identifies the specific class of securities (Common Stock of Amicus Therapeutics Inc.))
- 8 — Amendment Number (indicates this is the eighth amendment to BlackRock's Schedule 13G filing for Amicus Therapeutics Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person filing the SC 13G/A
- Amicus Therapeutics Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 8 (dollar_amount) — the specific amendment number for this filing
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Amicus Therapeutics Inc. throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What company's securities are the subject of this filing?
The subject company is AMICUS THERAPEUTICS, INC., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.' and 'AMICUS THERAPEUTICS INC (Name of Issuer)'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement)'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding AMICUS THERAPEUTICS, INC. (FOLD).